<DOC>
	<DOCNO>NCT02299570</DOCNO>
	<brief_summary>This first prospective , multi-center , double-blinded , randomize control study microbiota suspension derive intestinal microbe . Patients least two recurrence C. difficile infection ( CDI ) primary episode complete least two round standard-of-care oral antibiotic therapy least two episode severe CDI result hospitalization may eligible study . Patients whose CDI return less 8 week last assigned study treatment may eligible receive 2 treatment RBX2660 open-label portion study .</brief_summary>
	<brief_title>Microbiota Restoration Therapy Recurrent Clostridium Difficile Infection</brief_title>
	<detailed_description>This first prospective , multi-center , double-blinded , randomize control study microbiota suspension derive intestinal microbe . The primary assessment study ( ) efficacy RBX2660 compare placebo 8 week ( ii ) safety via assessment adverse event . Study visit 1- , 4- 8-weeks treatment additional follow-up 3 , 6 12 24 month post treatment . Patients least two recurrence C. difficile infection ( CDI ) primary episode complete least two round standard-of-care oral antibiotic therapy least two episode severe CDI result hospitalization may eligible study . Patients whose CDI return less 8 week last assigned study treatment may eligible receive 2 treatment RBX2660 open-label portion study .</detailed_description>
	<mesh_term>Enterocolitis</mesh_term>
	<criteria>â‰¥ 18 year Medical record documentation recurrent CDI either : ) least two recurrence primary episode complete least two round standardofcare oral antibiotic therapy b ) least two episode severe CDI result hospitalization . Documented history subject 's recurrent CDI control antibiotic even subject currently antibiotic . A positive stool test presence C. difficile within 60 day prior enrollment . A known history continue C. difficile diarrhea take course antibiotic prescribe CDI treatment . Requires antibiotic therapy condition recurrent CDI . Previous fecal transplant prior study enrollment . History inflammatory bowel disease ( IBD ) , e.g. , ulcerative colitis , Crohn 's disease , microscopic colitis . History irritable bowel syndrome ( IBS ) . History chronic diarrhea . History celiac disease . Colostomy . Planned surgery require perioperative antibiotic within 6 month study enrollment . Life expectancy &lt; 12 month . Compromised immune system .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>C diff</keyword>
	<keyword>CDI</keyword>
	<keyword>CDAD</keyword>
	<keyword>Fecal transplant</keyword>
	<keyword>Fecal Microbiota Transplant</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>FMT</keyword>
	<keyword>Microbiota restoration therapy</keyword>
	<keyword>Microbiota suspension</keyword>
	<keyword>Fecal bacteriotherapy</keyword>
	<keyword>C diff diarrhea</keyword>
</DOC>